

Epizyme, Inc.  
Form 8-K  
May 21, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): May 18, 2018**

**EPIZYME, INC.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-35945**  
**(Commission**  
  
**File Number)**

**26-1349956**  
**(IRS Employer**  
  
**Identification No.)**

**400 Technology Square, Cambridge, Massachusetts**  
**(Address of Principal Executive Offices)**

**02139**  
**(Zip Code)**

**Registrant's telephone number, including area code: (617) 229-5872**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Epizyme, Inc. (the Company) held its Annual Meeting of Stockholders on May 18, 2018. The following is a summary of the matters voted on at that meeting.

- a) The stockholders of the Company elected Kevin T. Conroy, Carl Goldfischer, M.D. and Beth Seidenberg, M.D. as class II directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2021. The results of the stockholders' vote with respect to the election of the class II directors were as follows:

| Name                   | Votes For  | Votes    |                  |
|------------------------|------------|----------|------------------|
|                        |            | Withheld | Broker Non-Votes |
| Kevin T. Conroy        | 47,400,738 | 150,506  | 5,358,014        |
| Carl Goldfischer, M.D. | 47,346,935 | 204,309  | 5,358,014        |
| Beth Seidenberg, M.D.  | 47,352,335 | 198,909  | 5,358,014        |

- b) The stockholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the stockholders' vote with respect to such ratification were as follows:

| For        | Against | Abstain | Broker Non-Votes |
|------------|---------|---------|------------------|
| 52,826,682 | 23,582  | 58,994  |                  |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIZYME, INC.

Date: May 21, 2018

By: /s/ Robert B. Bazemore  
Robert B. Bazemore

President and Chief Executive Officer